ACR GUIDELINES Bundle (free trial)

Juvenile Idiopathic Arthritis Guidelines

American College of Rheumatology GUIDELINES Apps brought to you free of charge courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/622891

Contents of this Issue

Navigation

Page 4 of 9

Table 4. Drugs Drugs Brand JIA Dose IL-6 Tocilizumab Actemra Polyarticular • <30 mg : 10 mg/kg • ≥30 mg : 8 mg/kg Systemic • <30 mg : 12 mg/kg • ≥30 mg : 10 mg/kg IL-1 Anakinra Kineret No FDA-approved label Canakinumab Ilaris • ≥7.5 kg : 4 mg/kg IV subcut (Max: 300 mg ) q4wks Rilonacept Arcalyst No FDA-approved label Anti-TNF Adalimumab Humira Subcut • 10 kg to <15 kg : 10 mg every other week • 15 kg to <30 kg : 20 mg every other week • ≥30 kg : 40 mg every other week Certolizumab Cimzia No FDA-approved label Etanercept Enbrel 0.8 mg/kg subcut weekly, with a maximum of 50 mg per week Golimumab Simponi No FDA-approved label Infliximab Remicade No FDA-approved label Other Biologics Abatacept Orencia • <75 kg : 10 mg/kg IV • 75-100 kg : 750 mg IV • >100 mg : 1000 mg IV Rituximab Rituxan No FDA-approved label Calcineurin inhibitors Cyclosporine Neoral No FDA-approved label Tacrolimus Prograf No FDA-approved label DMARDs Leflunomide Arava, generic • <20 kg : PO 100 mg once, then 10 mg q2d • 20-40 kg : 100 mg daily × 2, then 10 mg daily • >40 mg : 100 daily × 3, then 20 mg daily Methotrexate Rasuvo, Otrexup 15 mg/m 2 subcut weekly

Articles in this issue

Archives of this issue

view archives of ACR GUIDELINES Bundle (free trial) - Juvenile Idiopathic Arthritis Guidelines